Mayo Clinic, Department of Anesthesiology, 4500 San Pablo Rd, Jacksonville, FL 32224, USA.
Expert Rev Neurother. 2011 Feb;11(2):185-98. doi: 10.1586/ern.11.2.
Sugammadex is the first in a new class of medications termed selective relaxant binding agents. This medication acts to encapsulate free circulating steroidal nondepolarizing neuromuscular blocking agents. The encapsulation of neuromuscular agents effectively decreases the amount of neuromuscular blocker interacting at the neuromuscular receptor. This binding has a very high association rate, rendering the incidence of residual block extremely low, while avoiding the side effects associated with traditional reversal agents. Currently approved for clinical use in over 50 countries, sugammadex was not approved by the US FDA in 2008 due to concerns over potential hypersensitivity reactions. It is hoped that further study and clinical experience will help to better define the risk associated with sugammadex and eventually lead to the approval of this novel medication in the USA.
舒更葡糖钠是首个被称为选择性松弛剂结合剂的新型药物类别。这种药物可以包裹游离循环的甾体类非去极化神经肌肉阻滞剂。神经肌肉阻滞剂的包裹有效减少了与神经肌肉受体相互作用的神经肌肉阻滞剂的数量。这种结合具有非常高的亲和力，使残留阻滞的发生率极低，同时避免了与传统逆转剂相关的副作用。舒更葡糖钠目前已在 50 多个国家获得临床批准，但由于对潜在过敏反应的担忧，2008 年未获得美国 FDA 的批准。希望进一步的研究和临床经验将有助于更好地确定与舒更葡糖钠相关的风险，并最终导致这种新型药物在美国获得批准。
